Entyvio Seen as Superior to Humira in Treating Active UC, Phase 3 Trial Shows

Entyvio Seen as Superior to Humira in Treating Active UC, Phase 3 Trial Shows
One year of treatment with Entyvio (vedolizumab) was found to be superior to Humira (adalimumab) in achieving disease remission in people with ulcerative colitis (UC), a common form of inflammatory bowel disease (IBD), Takeda announced.  A head-to-head comparison of these anti-inflammatory therapies was made in the VARSITY trial (NCT02497469), a Phase 3b, randomized, double-blind, multi-center study sponsored by the company.  Trial results were published in The New England Journal of Medicine in the study, “Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis”. AbbVie's Humira is an anti-inflammatory medication used to treat UC. Adalimumab is an anti-TNF therapy that works by blocking the inflammatory signaling molecule TNF (tumor necrosis factor). However, some patients either do not respond well to or cannot to
Subscribe or to access all post and page content.